- Home
- AVIR vs DSM Comparison
AVIR vs DSM Comparison
Compare AVIR & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- DSM
- Stock Information
- Founded
- AVIR 2012
- DSM 1989
- Country
- AVIR United States
- DSM United States
- Employees
- AVIR N/A
- DSM N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- DSM Investment Managers
- Sector
- AVIR Health Care
- DSM Finance
- Exchange
- AVIR Nasdaq
- DSM Nasdaq
- Market Cap
- AVIR 290.4M
- DSM 304.0M
- IPO Year
- AVIR 2020
- DSM N/A
- Fundamental
- Price
- AVIR $3.25
- DSM $5.94
- Analyst Decision
- AVIR Hold
- DSM
- Analyst Count
- AVIR 1
- DSM 0
- Target Price
- AVIR $6.00
- DSM N/A
- AVG Volume (30 Days)
- AVIR 353.8K
- DSM 161.7K
- Earning Date
- AVIR 11-12-2025
- DSM 01-01-0001
- Dividend Yield
- AVIR N/A
- DSM 3.97%
- EPS Growth
- AVIR N/A
- DSM N/A
- EPS
- AVIR N/A
- DSM N/A
- Revenue
- AVIR N/A
- DSM N/A
- Revenue This Year
- AVIR N/A
- DSM N/A
- Revenue Next Year
- AVIR N/A
- DSM N/A
- P/E Ratio
- AVIR N/A
- DSM N/A
- Revenue Growth
- AVIR N/A
- DSM N/A
- 52 Week Low
- AVIR $2.46
- DSM $4.69
- 52 Week High
- AVIR $4.02
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- AVIR 55.27
- DSM 44.31
- Support Level
- AVIR $3.18
- DSM $5.95
- Resistance Level
- AVIR $3.27
- DSM $6.01
- Average True Range (ATR)
- AVIR 0.09
- DSM 0.05
- MACD
- AVIR 0.00
- DSM -0.01
- Stochastic Oscillator
- AVIR 60.00
- DSM 10.27
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.